Related references
Note: Only part of the references are listed.Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women
Laura Y. Park-Wyllie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Bisphosphonate Use and Atypical Fractures of the Femoral Shaft
Jorg Schilcher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
R. Rizzoli et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial
Ann V. Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis
Bo Abrahamsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States
Sarah J. Glover et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study
Bo Abrahamsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial
Michael McClung et al.
OBSTETRICS AND GYNECOLOGY (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
John T. Grbic et al.
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION (2008)
Fracture risk remains reduced one year after discontinuation of risedronate
N. B. Watts et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Influence of baseline deformity definition on subsequent vertebral fracture risk in postmenopausal women
L. J. Melton et al.
OSTEOPOROSIS INTERNATIONAL (2006)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
KE Ensrud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Risk of new vertebral fracture in the year following a fracture
R Lindsay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures
MC Nevitt et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
